Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Friday announced the launch of AstraZeneca Direct, an online platform designed to provide eligible US patients with a simple, convenient way to access prescribed medications at a transparent cash price with home delivery.
The service targets patients with chronic conditions, including asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.
From October, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through the platform for up to 70% off the list price. FLUMIST (Influenza Vaccine Live, Intranasal) will also be available for home delivery.
Joris Silon, US country president at AstraZeneca, said that the platform complements AstraZeneca's existing patient support programmes and provides transparent pricing and convenient access.
The platform will be accessible at AstraZenecaDirect.com starting 1 October 2025.
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin